 NEW YORK, March 09, 2021 GLOBE NEWSWIRE -- TG Therapeutics, Inc. NASDAQ: TGTX today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQTM umbralisib, the Companys inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory indolent non-Hodgkin Lymphoma NHL in the Journal of Clinical Oncology JCO. 